Related Experiment Video
Updated: Feb 14, 2026

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis
Published on: June 3, 2016
Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial
Shuhong Gao1, Zhengzheng Shi2, Xin Li3
1Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Abstract:
Fatostatin, a chemical inhibitor of the sterol regulatory element‑binding protein (SREBP) pathway, has been reported to possess high antitumor activity against prostate and pancreatic cancer. The main aim of the present study was to investigate the effects and mechanism of fatostatin in endometrial carcinoma (EC). In the present study, we determined that fatostatin inhibited EC cell viability and colony formation capacity, decreased the invasive and migratory capacities of EC cells, induced EC cell cycle arrest at the G2/M phase and stimulated caspase‑mediated apoptosis of EC cells. In addition, fatostatin significantly decreased the protein expression levels of nuclear SREBPs and their downstream genes and increased the protein expression levels of cleaved caspase‑9, caspase‑3 and PARP in EC cells. In addition, the mRNA expression levels of SREBP‑controlled downstream genes were also significantly downregulated. The quantification assays of fatty acids and total cholesterol revealed that the levels of free fatty acids and total cholesterol in EC cells were decreased. The present study indicated that fatostatin exhibited antitumor effects by blocking SREBP‑regulated metabolic pathways and inducing caspase‑mediated apoptosis in EC and may be a potent therapeutic strategy for the treatment of EC.
Insights
Fatostatin effectively inhibits endometrial carcinoma (EC) cell growth and spread by blocking sterol regulatory element-binding protein (SREBP) pathways. This compound induces apoptosis and may offer a new therapeutic strategy for EC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Fatostatin is a sterol regulatory element-binding protein (SREBP) pathway inhibitor with known antitumor activity.
- Endometrial carcinoma (EC) is a significant gynecological malignancy requiring novel therapeutic approaches.
Purpose of the Study:
- To investigate the antitumor effects and underlying mechanisms of fatostatin in endometrial carcinoma (EC) cells.
- To determine if fatostatin can inhibit EC cell proliferation, invasion, and migration.
- To elucidate the impact of fatostatin on SREBP pathway activity and apoptosis in EC.
Main Methods:
- Cell viability and colony formation assays were performed to assess proliferation.
- Invasion and migration assays were used to evaluate cellular motility.
- Western blotting was employed to measure protein expression levels of SREBPs, downstream targets, and apoptosis markers (caspase-9, caspase-3, PARP).
- Quantitative assays measured free fatty acid and total cholesterol levels.
Main Results:
- Fatostatin significantly inhibited EC cell viability, colony formation, invasion, and migration.
- Fatostatin induced cell cycle arrest at the G2/M phase and promoted caspase-mediated apoptosis.
- Protein and mRNA levels of nuclear SREBPs and their downstream genes were downregulated.
- Levels of free fatty acids and total cholesterol were decreased in EC cells treated with fatostatin.
Conclusions:
- Fatostatin demonstrates potent antitumor effects in endometrial carcinoma by inhibiting SREBP-regulated metabolic pathways.
- The mechanism involves downregulation of SREBP activity, induction of apoptosis, and reduction of key metabolites.
- Fatostatin represents a promising therapeutic candidate for endometrial carcinoma treatment.
Related Concept Videos
Regulation of Metabolism
What is Metabolism?
GTPases and their Regulation
Large G-proteins,...
Apoptosis
Negative Regulator Molecules
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...

